Skip to Main Content

Paper Details

The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
BJU Int
1
2024
Author NameAffiliation
Pavlos MsaouelThe University of Texas MD Anderson Cancer Center
Pavlos MsaouelThe University of Texas MD Anderson Cancer Center
Pavlos MsaouelDavid H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2